-+ 0.00%
-+ 0.00%
-+ 0.00%

Genprex's Gene Therapy Shows Results for Lung Cancer Treatment at AACR Meeting

Benzinga·04/30/2025 11:36:02
Listen to the news

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of KRASG12C mutant non-small cell lung cancer (NSCLC). This data were presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025 in Chicago, Illinois.